PRETORIA (16 November, 2022)—A new study published in PLOS Global Public Health found that the BPaLM/BPaL treatment regimen that will
Imagining a TB-free world amidst resurgence during COVID-19 pandemic NEW YORK (March 24, 2022)—The world continues to battle against two
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug NEW YORK and
He will bring more than 20 years of global and country level experience in TB and a people-centered approach to
NEW YORK (March 24, 2021)—TB Alliance is excited to announce the expansion of its Access Advisory Committee (AAC) to include
New Clinical Access Program to Expand Access to Tuberculosis Treatment Pretoria, 10 December 2020—TB Alliance welcomes the Wits Health Consortium
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder
PRETORIA — Today marks the one year anniversary of the US FDA’s approval of pretomanid as part of the BPaL
The NPAP is designed for patients in countries where regulatory approval or other access mechanisms for pretomanid are not yet
NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned
